PACS Group (PACS) Q2 2026 earnings review
Operating Leverage Drives Guidance Raise, But Cohort Cracks Emerge
PACS delivered another beat-and-raise quarter, increasing its FY26 Adjusted EBITDA guidance by ~6% at the midpoint to $640-$660 million. The company's 'buy and fix' strategy generated massive operating leverage—revenue grew 9.1% YoY, but Net Income surged nearly 50% and Adjusted EBITDA grew 25%. However, beneath the robust headline numbers, the core operational engine showed slight fatigue: occupancy rates in both the 'Mature' and 'New' facility cohorts regressed year-over-year. The newly announced 34-facility Eduro acquisition signals a return to aggressive M&A, ensuring top-line growth but increasing near-term integration risk.
🐂 Bull Case
The company generated an impressive $371.8 million in operating cash flow over the first six months of 2026. This allows PACS to self-fund real estate purchases ($190.8M YTD) without straining its balance sheet.
After a quiet integration period, the 34-facility Eduro transaction injects fresh turnaround inventory into the pipeline. The swift closure of the first 20 Texas facilities proves the integration team is back at full speed.
🐻 Bear Case
Despite a strong overall occupancy of 90.4%, the Mature cohort dropped from 94.7% to 93.8% YoY. If the 'finished product' facilities are losing census, long-term margin ceilings may be lower than modeled.
High margins are partially sustained by opaque state-level programs like California's WQIP. Changes to state Medicaid budgets pose an outsized risk to bottom-line stability.
⚖️ Verdict: 🟢
Bullish. The 25% Adjusted EBITDA growth on 9% revenue growth proves the turnaround model's immense profitability. While minor cohort occupancy dips warrant monitoring, the Eduro acquisition and guidance raise confirm the growth story remains highly intact.
Key Themes
Macro: The 'Silver Tsunami' Demand Floor
The aging U.S. demographic provides a structural tailwind that PACS is capturing better than competitors. While the broader skilled nursing industry languishes at a 79.5% average occupancy rate, PACS maintains a 90.4% overall rate. This 1,000+ basis point premium insulates the company from minor referral fluctuations and guarantees a high baseline of asset utilization.
Innovation: Hundreds of Millions in Tech Platform Support
PACS's competitive advantage isn't just local leadership; it's the proprietary centralized technology stack. Management has invested hundreds of millions to build digital infrastructure that gives local administrators real-time data on labor costs, compliance, and clinical outcomes. This technology allows a newly acquired failing facility to quickly adopt standard operating procedures and reduce costly regulatory deficiencies.
Eduro Deal Restarts Inorganic Growth
The 34-facility Eduro acquisition across six western states signals that PACS is done digesting its massive 2024 vintage and is returning to active M&A. This is a critical driver, as newly acquired facilities provide the raw material for the margin expansion engine. The updated guidance explicitly prices in the initial 20 Eduro facilities closed on August 1, providing immediate top-line accretion.
Contradiction: Cohort Occupancy Slipping Despite 'Excellent' Narrative
Management's press release touted the 'continued excellent performance of our portfolio across all cohorts.' However, the data directly contradicts this for the bookends of the portfolio. The 'New' cohort occupancy fell sharply from 80.5% in 25Q2 to 78.7% in 26Q2. More worryingly, the 'Mature' cohort—the company's profit engine—saw occupancy slip from 94.7% to 93.8% over the same period. This indicates potential census leakage in facilities that are supposed to be fully optimized.
Heavy Real Estate Capital Requirements
The company deployed $104.3 million to acquire real estate in Q2 alone, bringing the six-month total to $190.8 million. While owning the underlying real estate prevents future lease escalations and captures created value, it is highly capital intensive. This aggressive deployment limits the cash available to execute the newly announced $250 million share repurchase program, acting as an anchor on capital return.
State-Level Quality Policy Risk
PACS benefits significantly from state-specific quality programs, most notably California's Workforce & Quality Incentive Program (WQIP). Because the timing and existence of these payouts are highly unpredictable, management routinely excludes them from guidance. If state budget deficits force the curtailment of programs like WQIP or similar initiatives in Ohio, PACS will lose a high-margin revenue stream that investors have grown accustomed to.
Other KPIs
Grew 5.8% YoY for the 284 facilities operational at the beginning of 2025. This proves the company doesn't solely rely on M&A to grow the top line. Same-store occupancy also expanded by 150 basis points YoY to 90.6%, proving the ongoing operational improvements inside the existing footprint.
Improved slightly from 49.4% in the prior year. Capturing higher-acuity Medicare and Managed Care patients is the key to margin expansion. Notably, the 'New' cohort showed excellent progress, driving skilled mix by revenue from 38.9% in Q2 2025 up to 44.3% in Q2 2026.
Guidance
Accelerating. Raised from the prior range of $5.65 - $5.75 billion. This includes partial-year contributions from the 20 newly closed Texas facilities from the Eduro deal, but implies continued underlying strength in daily rates across the broader portfolio.
Accelerating. Raised from the prior $605 - $625 million range. The $650 million midpoint represents roughly 29% growth over FY25. This hike confirms that the 24.6% EBITDA growth posted in Q2 is a sustainable run rate, driven by disciplined cost controls and maturing facility margins.
Key Questions
New Cohort Occupancy Decline
Occupancy in the 'New' facility cohort fell to 78.7% this quarter. Is this a function of acquiring deeply distressed assets with extremely low starting censuses, or are we seeing higher initial patient attrition during the integration phase?
Mature Cohort Growth Ceiling
With Mature occupancy sliding slightly to 93.8% year-over-year, have we reached the natural ceiling for census in these facilities? If volume growth is tapped out, how much pricing power remains to drive further organic growth in this cohort?
Eduro Margin Impact
You've baked the 20 Eduro Texas facilities into the updated guidance. Given that these are fresh integrations, should we expect a temporary drag on consolidated margins over the next two quarters as they enter the 'Ramping' phase?
Share Repurchase Execution
With $190 million already deployed into real estate this year and M&A activity resuming via Eduro, how aggressively should investors expect you to execute on the newly authorized $250 million share repurchase program?